Published: May 07, 2021
-Xenter’s Expanding Team of Industry Leaders Poised to Advance Device/Data/Drug Technologies for Interventional Medicine, Pharmaceutical Advancements and Digital Health-
SALT LAKE CITY (BUSINESS WIRE) Xenter, Inc. (XenterMD.com), the world’s first start-up Device-Data-Drug healthcare technologies company, today announced the appointment of four additional industry leaders to its Board of Directors and the closing of a $12M Series A offering of preferred stock. The additional members are
Robert S. Langer, an Institute Professor at MIT and the most cited engineer in history and 4th most cited individual in any field who has authored more than 1,500 scientific papers. He is also a co-founder and board member of Moderna.
Share:
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K. Stankovic, MD, PhD, MSPH, to the company s Board of Directors. Dr. Stankovic is a seasoned leader with more than 30 years of research and development experience in academic, government,
in vitro diagnostic and device industry settings.
Dr. Stankovic is currently managing partner at Koliada Consulting, LLC, a firm focused on biotech, medical devices and
in vitro diagnostics. Previously, she was Senior Vice President, World Wide Regional Medical Affairs and Global Health, for Becton, Dickinson and Company (BD). Dr. Stankovic served in senior roles at BD for more than a decade, leading medical affairs and clinical operations for various BD business units.